


## NEW PRODUCTS

### *The Latest in the Medical Marketplace*




#### **New Type 2 Diabetes Drug**

Liraglutide (Victoza), the first once-daily human glucagon-like peptide 1 analogue developed for type 2 diabetes therapy, has been approved by the FDA as second-line monotherapy treatment or use in combination treatment of the disease. It works by stimulating the release of insulin from pancreatic  $\beta$  cells only when blood sugar levels are high. Distributed by Novo Nordisk, liraglutide does not cause weight gain (in contrast to many other diabetes medications), but it is not recommended as first-line therapy in patients who do not have well-controlled glycemic levels on diet and exercise. **Prescribing and other information is available at [www.victoza.com](http://www.victoza.com).**




#### **New Formulation of Prenatal Vitamins**

PreNexa prescription prenatal vitamins are available in a new formulation with increased amounts of algal-oil, plant-based docosahexaenoic acid (300 mg) and vitamin D3 (400 IU). The once-daily supplement, available from Upsher-Smith Laboratories, is available in bottles of 30 gel capsules. **More information is online at [www.prenexa.com](http://www.prenexa.com).**



#### **Breast Cancer Drug Indication Expanded**

The FDA has approved an expanded indication for lapatinib (Tykerb), to be used in combination with letrozole (Femara) for treatment of hormone-positive and human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated. Manufactured by



GlaxoSmithKline, lapatinib was initially approved in combination with capecitabine to treat advanced breast cancer patients with the HER2 protein who had received prior treatment with anthracycline and trastuzumab. **See [www.tykerb.com](http://www.tykerb.com) for complete product information.**

#### **Tubal Occlusion Diagnostic Set**

FluoroSet, a comprehensive, 3-device radiographic tubal assessment product, is now available from Cook Medical. An intrauterine access balloon catheter injects contrast medium into the uterus and fallopian tubes for hysterosalpingography. A second catheter is used for salpingography and evaluation of tubal patency. The third device enhances control and high radiopacity. The new diagnostic tool simplifies tubal occlusion assessment, while easing patient discomfort. **More information can be found at [www.cookmedical.com](http://www.cookmedical.com).**

#### **Uterine Manipulator/Injectors**

New capabilities of UMI and UMI-Loc products from Cook Medical improve manipulation or repositioning of the uterus during diagnostic and surgical procedures and the injection of medium into the uterine cavity for diagnostic purposes. The single-use devices help maneuver the uterus for better access to target tissues and to facilitate dye injection. The UMI and UMI-Loc are disposable and easy to use, with catheter markings to gauge accurate placement and an innovative shape for easy insertion and maneuverability. **To view product details, access [www.cookmedical.com](http://www.cookmedical.com).**

## New Prevention Indication for Statin

Rosuvastatin (Crestor) is now FDA approved for the prevention of cardiovascular disease in patients with no clinically evident heart disease but increased risk for the condition due to the combined effect of age ( $\geq 50$  in men;  $\geq 60$  in women), C-reactive protein  $\geq 2$  mg/L, and at least one other cardiovascular risk factor (eg, hypertension, smoking, family history). Marketed by AstraZeneca, the statin has been available since 2003 for lowering cholesterol and triglycerides and slowing the progression of athero-

sclerosis. More information is online at [www.crestor.com](http://www.crestor.com).

## New RA Treatment Approved

Tocilizumab (Actemra) has been approved by the FDA for treatment of adults with moderate to severe rheumatoid arthritis (RA) who have inadequate response to or cannot tolerate other RA drugs. Marketed by Genentech Inc, tocilizumab works by blocking the action of interleukin 6, which is overabundant in people with RA. For more information, see [www.actemra.com](http://www.actemra.com).


## Therapy for Major Depression

The FDA has approved quetiapine fumarate (Seroquel XR; 150 to 300 mg) as adjunctive therapy for major depressive disorder in patients with inadequate response to their current antidepressant. The once-daily atypical antipsychotic, manufactured by AstraZeneca, already has several indications, including treatment of bipolar disorder and schizophrenia. Full prescribing information is available at [www.seroquelxr.com](http://www.seroquelxr.com).

[www.femalepatient.com](http://www.femalepatient.com)

# Look for our Patient Handouts online

An extensive array of topics are available in English and Spanish and are ready to print out for your reception area and examination rooms.



[www.femalepatient.com](http://www.femalepatient.com)